Pyrimidine compound as JAK kinase inhibitor
AssigneeTheravance Biopharma R&D IP, LLC
InventorsJennifer Kozak, Ryan Hudson, Gary E. L. Brandt, Robert Murray McKinnell, Marta Dabros, Jerry Nzerem
Life of this patent
Estimating the term…
Abstract
The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
Claims32
A compound of formula (I):
- or a pharmaceutically-acceptable salt thereof.
A compound of formula (I):
A crystalline form of the compound of formula (I):
- wherein the crystalline form is characterized by a powder X-ray diffraction pattern comprising diffraction peaks at 20 values of 11.4±0.2, 16.2±0.2, 16.6±0.2, 17.7±0.2, and 21.9±0.2.
A process for preparing a compound of formula (I):
- or a pharmaceutically acceptable salt thereof, comprising:
- (a) reacting a compound of formula (II):
- wherein R is a C1-12 alkyl group, with a reducing agent and
- (b) optionally forming a pharmaceutically acceptable salt to provide a compound of formula (I), or a pharmaceutically acceptable salt thereof.
A compound of formula (II):
- or a pharmaceutically acceptable salt thereof,
- wherein R is a C1-12 alkyl group.
A compound of formula (III):
- or a pharmaceutically acceptable salt thereof,
- wherein R is a C1-12 alkyl group and X is halogen.
Dependencies are inferred from the claim text.